SCYNEXIS, Inc. is a pharmaceutical company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate, SCY-078, is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug resistant strains. In addition, the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635, which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641, which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.
